| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Grant and award revenue | 1,159 | 2,169 | 491 | 2,973 |
| Research and development | 5,824 | 6,394 | 5,429 | 9,485 |
| General and administrative | 3,111 | 2,619 | 3,253 | 3,244 |
| Total operating expenses | 8,935 | 9,013 | 8,682 | 12,729 |
| Operating loss | -7,776 | -6,844 | -8,191 | -9,756 |
| Interest income | 90 | 108 | 59 | 294 |
| Interest expense | 4,346 | 3,808 | 3,602 | 2,923 |
| Change in fair value of the convertible loan | -14,643 | -5,751 | 5,203 | 6,904 |
| Total other income (expense), net | -18,899 | -9,451 | 1,660 | 4,275 |
| Net loss | -26,675 | -16,295 | -6,531 | -5,481 |
| Earnings per share, basic | -0.74 | -0.45 | -0.18 | -0.15 |
| Earnings per share, diluted | -0.74 | -0.45 | -0.2 | -0.15 |
| Weighted average number of shares outstanding, basic | 36,226,285 | 36,193,479 | 36,184,802 | 36,180,124 |
| Weighted average number of shares outstanding, diluted | 36,226,285 | 36,193,479 | 59,478,662 | 36,180,124 |
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)